Phuturdex › Listed companies › Cellectis S.A.
Companies listed in the US · updated 13 November 2026
Cellectis S.A.: drugs in development, dates and SEC filings
Data from official sources, not financial advice.
As of 13 November 2026 Cellectis S.A. sponsors 3 active clinical trials (recruiting or ongoing, phases I–III) on 4 identified drugs. 4 are experimental (not yet approved in the United States).
Official links
Pipeline by phase
Drugs in the active trials sponsored by Cellectis S.A., with the most advanced phase of those trials. Sorted by phase and number of trials.
| Drug | Most advanced phase | Main diseases |
|---|---|---|
| CLLS52 | I–II | B-cell lymphoma, Burkitt lymphoma |
| UCART20x22 | I–II | B-cell lymphoma |
| UCART22 | I–II | Burkitt lymphoma |
| UCART123v1.2 | I | Acute myeloid leukemia |
Upcoming dates
Expected primary completion of the company’s phase II and III trials (12 months, date stated by the sponsor on ClinicalTrials.gov) and regulatory dates of the products the company holds (36 months). Below, the dates of the current month.
No date in the current month.
Upcoming dates in all: 1. Sign up free to see everything →
US exclusivities and patents expiring
Products whose FDA application is held by the company (Orange Book or Purple Book), expiring in the next 36 months.
No US patent or exclusivity expiring in the next 36 months for the products the company holds.
Recent events (last 12 months)
The company’s trials terminated, suspended or withdrawn and new phase III trials (ClinicalTrials.gov); approvals, opinions and designations of the products the company holds (FDA, EMA).
No event in the last 12 months in the linked official sources.
Financial figures from the latest SEC report
Figures as reported by the company in its SEC filing (XBRL data), in the currency of the filing, with no Phuturdex calculation. Fiscal year (IFRS or US GAAP statements): 20-F report for the period ended 31 December 2025, filed 20 March 2026.
| Item | Value | Period | Filing |
|---|---|---|---|
| Cash and cash equivalentsifrs-full:CashAndCashEquivalents | USD 61.5 million | at 31 December 2025 | 20-F · 20 Mar 2026 |
| Research and development expenseifrs-full:ResearchAndDevelopmentExpense | USD 93.5 million | 1 January 2025 to 31 December 2025 | 20-F · 20 Mar 2026 |
| Revenueifrs-full:Revenue | USD 72.9 million | 1 January 2025 to 31 December 2025 | 20-F · 20 Mar 2026 |
Recent SEC filings
| Filing | Filed | Reference date |
|---|---|---|
| 6-K | 12 Nov 2026 | 12 Nov 2026 |
| 6-K | 9 Nov 2026 | 9 Nov 2026 |
| 6-K | 28 Oct 2026 | 27 Oct 2026 |
| 6-K | 14 Sep 2026 | 14 Sep 2026 |
| 6-K | 11 Sep 2026 | 11 Sep 2026 |
| 6-K | 1 Sep 2026 | 1 Sep 2026 |
All the data on Cellectis S.A.
In Phuturdex you get every trial of the company with countries and dates, the catalyst calendar, email alerts when something changes and PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Sources: SEC EDGAR (exchange, ticker, filings and XBRL financial data, US Government works); ClinicalTrials.gov (U.S. National Library of Medicine), FDA (Drugs@FDA, Orange and Purple Book, orphan drugs) and EMA, data processed by Phuturdex and updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. The sponsor is the one stated by each trial; company names are linked to the SEC only when they are the same apart from the legal form. Patents, exclusivities, approvals and opinions are attributed to the company only when it holds them in the official register. No stock prices or charts. Only the official sources are authoritative.
Data from official sources, not financial advice.